

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) May 1, 2012

**BECTON, DICKINSON AND COMPANY**

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

---

001-4802

(Commission File Number)

22-0760120

(IRS Employer Identification No.)

---

1 Becton Drive, Franklin Lakes, New Jersey

(Address of Principal Executive Offices)

07417-1880

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

## ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On May 1, 2012, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2012. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

- Revenues. We present international and total revenue growth rates (for the total company and each of its segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that these measures of revenue growth allow investors to better understand the underlying operating results of BD and facilitate comparisons to prior periods.
- Earnings Per Share from Continuing Operations. We present the percentage growth or decrease in earnings per share from continuing operations for the second quarter and first six months of fiscal year 2012 compared to the prior year periods after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD and facilitates comparisons to prior periods.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

---

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated May 1, 2012, which is furnished pursuant to Item 2.02

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Gary DeFazio  
Gary DeFazio  
Vice President and Corporate Secretary

Date: May 1, 2012

99.1 Press release dated May 1, 2012, which is furnished pursuant to Item 2.02

1 Becton Drive  
Franklin Lakes, NJ 07417  
www.bd.com

News Release



Contact:

Monique N. Dolecki, Investor Relations – 201-847-5453  
Colleen T. White, Corporate Communications – 201-847-5369

**BD ANNOUNCES RESULTS FOR 2012 SECOND FISCAL QUARTER**

**Franklin Lakes, NJ (May 1, 2012)**– BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$1.991 billion for the second fiscal quarter ended March 31, 2012, representing an increase of 3.6 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis.

“We are very pleased with our second quarter results. We posted solid revenue growth led by our BD Medical and BD Diagnostics segments, despite continuing challenges in the U.S. in our BD Biosciences segment,” said Vincent A. Forlenza, Chief Executive Officer and President. “We remain committed to our strategy of investing and innovating for growth, both organically and through acquisitions such as KIESTRA Lab Automation.”

---

**Agreement to Sell Discovery Labware Unit, Excluding Advanced Bioprocessing**

In April 2012, the Company signed a definitive agreement to sell its BD Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing platform. The transaction is expected to be completed by the end of calendar year 2012, subject to the satisfaction of customary closing conditions, including consultations and regulatory approvals. For the full fiscal year 2012, revenues and earnings per share associated with this asset group are estimated at \$235 million and \$0.23 to \$0.27, respectively. The Company expects to record a gain on the sale at the time the transaction is completed.

**Second Quarter and Six-Month Fiscal 2012 Operating Results**

As expected, reported diluted earnings per share from continuing operations for the second quarter were \$1.38, or flat compared with the prior-year period. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the second quarter increased by 2.9 percent.

For the six-month period ending March 31, 2012, reported diluted earnings per share from continuing operations were \$2.59, compared with \$2.72 in the prior-year period. This represents a decrease of 4.8 percent, or 3.3 percent on a currency-neutral basis.

**Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$1.021 billion, representing an increase of 4.1 percent compared with the prior-year period, or 5.3 percent on a currency-neutral basis. The segment's revenue growth reflected strong sales in the Pharmaceutical Systems and Diabetes Care

---

units and solid sales in the Medical Surgical Systems unit. For the six-month period ended March 31, 2012, BD Medical revenues increased 3.3 percent, or 4.0 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$630 million, representing an increase of 4.1 percent compared with the prior-year period, or 5.0 percent on a foreign currency-neutral basis. The segment's growth was primarily driven by strong sales in the Preanalytical Systems unit and solid growth in Women's Health and Cancer. For the six-month period ended March 31, 2012, BD Diagnostics revenues increased 3.6 percent, or 4.1 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$340 million, representing an increase of 1.3 percent compared with the prior-year period, or 1.7 percent on a foreign currency-neutral basis. Segment growth was primarily driven by clinical reagent sales in the Cell Analysis unit and strong emerging market sales as overall segment growth continues to be negatively affected by weakness in the U.S. research market. For the six-month period ended March 31, 2012, BD Biosciences revenues increased 1.1 percent, or 1.0 percent on a currency-neutral basis.

#### **Geographic Results**

Second quarter revenues in the U.S. were \$848 million, representing an increase of 2.2 percent compared with the prior-year period. Revenues outside of the U.S. were \$1.143 billion, representing an increase of 4.6 percent compared with the prior-year period, or an increase of 6.3 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products. For the six-month period ended March 31, 2012, revenues in the U.S. were \$1.676 billion, representing an increase of 1.1 percent compared with



---

the prior-year period. Revenues outside of the U.S. were \$2.202 billion, representing an increase of 4.5 percent when compared with the prior-year period, or 5.4 percent on a foreign currency-neutral basis.

**Fiscal 2012 Outlook for Full Year**

The Company is raising its previous guidance for reported revenue growth for the full fiscal year 2012 from about flat to be between 1 to 2 percent. This reflects the anticipated effects of favorable currency translation. On a currency-neutral basis, the Company is raising the lower end of its previous revenue growth guidance of 2 to 4 percent, to 3 to 4 percent. The Company is raising reported diluted earnings per share from continuing operations for fiscal year 2012 from \$5.60 to \$5.70 to be between \$5.68 and \$5.73, and plans to repurchase, subject to market conditions, \$1.5 billion of its common stock in fiscal year 2012.

**Conference Call Information**

A conference call regarding BD's second quarter results and its expectations for the full fiscal year 2012 will be broadcast live on BD's website [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 8:00 a.m. (ET) Tuesday, May 1, 2012. The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, May 8, 2012, access code 68128968.

**Non-GAAP Financial Measures**

---

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

**About BD**

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*

*This press release, including the section entitled "Fiscal 2012 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; changes in interest or foreign currency exchange rates; competitive factors; pricing and other market pressures; our ability to successfully integrate any businesses we acquire; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain*

---

*favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.*

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended March 31,		% Change
	2012	2011	
REVENUES	\$1,990,818	\$1,922,023	3.6
Cost of products sold	970,832	920,589	5.5
Selling and administrative	495,020	441,942	12.0
Research and development	118,528	119,152	(0.5)
TOTAL OPERATING COSTS AND EXPENSES	1,584,380	1,481,683	6.9
OPERATING INCOME	406,438	440,340	(7.7)
Interest income	16,678	14,564	14.5
Interest expense	(35,140)	(23,921)	46.9
Other income (expense), net	4,657	(2,522)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	392,633	428,461	(8.4)
Income tax provision	102,085	117,399	(13.0)
INCOME FROM CONTINUING OPERATIONS	290,548	311,062	(6.6)
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(140) AND \$377, RESPECTIVELY	485	957	(49.3)
NET INCOME	\$ 291,033	\$ 312,019	(6.7)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.41	\$ 1.41	—
Income from discontinued operations	\$ —	\$ —	—
Net income	\$ 1.41	\$ 1.41	—
Diluted:			
Income from continuing operations	\$ 1.38	\$ 1.38	—
Income from discontinued operations	\$ —	\$ —	—
Net income (1)	\$ 1.39	\$ 1.38	0.7
AVERAGE SHARES OUTSTANDING			
Basic	206,426	220,894	
Diluted	209,803	225,467	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	Six Months Ended March 31,		% Change
	2012	2011	
REVENUES	\$3,878,464	\$3,764,028	3.0
Cost of products sold	1,897,015	1,786,020	6.2
Selling and administrative	983,978	889,897	10.6
Research and development	232,464	234,693	(0.9)
TOTAL OPERATING COSTS AND EXPENSES	3,113,457	2,910,610	7.0
OPERATING INCOME	765,007	853,418	(10.4)
Interest income	32,126	29,786	7.9
Interest expense	(64,518)	(39,474)	63.4
Other income (expense), net	4,272	(7,118)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	736,887	836,612	(11.9)
Income tax provision	183,328	211,273	(13.2)
INCOME FROM CONTINUING OPERATIONS	553,559	625,339	(11.5)
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(159) AND \$601, RESPECTIVELY	460	2,617	(82.4)
NET INCOME	\$ 554,019	\$ 627,956	(11.8)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 2.63	\$ 2.79	(5.7)
Income from discontinued operations	\$ —	\$ 0.01	NM
Net income	\$ 2.63	\$ 2.80	(6.1)
Diluted:			
Income from continuing operations	\$ 2.59	\$ 2.72	(4.8)
Income from discontinued operations	\$ —	\$ 0.01	NM
Net income (1)	\$ 2.59	\$ 2.74	(5.5)
AVERAGE SHARES OUTSTANDING			
Basic	210,385	224,528	
Diluted	213,970	229,529	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	Three Months Ended March 31,		
	2012	2011	% Change
<b>BD MEDICAL</b>			
United States	\$ 418,521	\$ 398,487	5.0
International	602,666	582,845	3.4
TOTAL	\$1,021,187	\$ 981,332	4.1
<b>BD DIAGNOSTICS</b>			
United States	\$ 318,597	\$ 310,617	2.6
International	311,422	294,730	5.7
TOTAL	\$ 630,019	\$ 605,347	4.1
<b>BD BIOSCIENCES</b>			
United States	\$ 110,502	\$ 120,077	(8.0)
International	229,110	215,267	6.4
TOTAL	\$ 339,612	\$ 335,344	1.3
<b>TOTAL REVENUES</b>			
United States	\$ 847,620	\$ 829,181	2.2
International	1,143,198	1,092,842	4.6
TOTAL	\$1,990,818	\$1,922,023	3.6

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	Six Months Ended March 31,		% Change
	2012	2011	
<b>BD MEDICAL</b>			
United States	\$ 833,190	\$ 804,014	3.6
International	<u>1,138,394</u>	<u>1,103,863</u>	<u>3.1</u>
TOTAL	<u>\$1,971,584</u>	<u>\$1,907,877</u>	<u>3.3</u>
<b>BD DIAGNOSTICS</b>			
United States	\$ 630,220	\$ 619,467	1.7
International	<u>620,542</u>	<u>587,603</u>	<u>5.6</u>
TOTAL	<u>\$1,250,762</u>	<u>\$1,207,070</u>	<u>3.6</u>
<b>BD BIOSCIENCES</b>			
United States	\$ 213,003	\$ 234,302	(9.1)
International	<u>443,115</u>	<u>414,779</u>	<u>6.8</u>
TOTAL	<u>\$ 656,118</u>	<u>\$ 649,081</u>	<u>1.1</u>
<b>TOTAL REVENUES</b>			
United States	\$1,676,413	\$1,657,783	1.1
International	<u>2,202,051</u>	<u>2,106,245</u>	<u>4.5</u>
TOTAL	<u>\$3,878,464</u>	<u>\$3,764,028</u>	<u>3.0</u>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		
	2012	2011	% Change
<b><u>BD MEDICAL</u></b>			
Medical Surgical Systems	\$237,599	\$234,571	1.3
Diabetes Care	105,725	95,939	10.2
Pharmaceutical Systems	75,197	67,977	10.6
<b>TOTAL</b>	<b>\$418,521</b>	<b>\$398,487</b>	<b>5.0</b>
<b><u>BD DIAGNOSTICS</u></b>			
Preanalytical Systems	\$163,455	\$156,978	4.1
Diagnostic Systems	155,142	153,639	1.0
<b>TOTAL</b>	<b>\$318,597</b>	<b>\$310,617</b>	<b>2.6</b>
<b><u>BD BIOSCIENCES</u></b>			
Cell Analysis	\$ 78,841	\$ 83,006	(5.0)
Discovery Labware	31,661	37,071	(14.6)
<b>TOTAL</b>	<b>\$110,502</b>	<b>\$120,077</b>	<b>(8.0)</b>
<b>TOTAL UNITED STATES</b>	<b>\$847,620</b>	<b>\$829,181</b>	<b>2.2</b>



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	International				
	2012	2011	Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 281,340	\$ 270,020	4.2	6.0	(1.8)
Diabetes Care	113,520	111,820	1.5	3.3	(1.8)
Pharmaceutical Systems	207,806	201,005	3.4	5.9	(2.5)
<b>TOTAL</b>	<b>\$ 602,666</b>	<b>\$ 582,845</b>	<b>3.4</b>	<b>5.4</b>	<b>(2.0)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 159,858	\$ 149,261	7.1	9.6	(2.5)
Diagnostic Systems	151,564	145,469	4.2	5.5	(1.3)
<b>TOTAL</b>	<b>\$ 311,422</b>	<b>\$ 294,730</b>	<b>5.7</b>	<b>7.6</b>	<b>(1.9)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 182,702	\$ 172,510	5.9	6.6	(0.7)
Discovery Labware	46,408	42,757	8.5	8.7	(0.2)
<b>TOTAL</b>	<b>\$ 229,110</b>	<b>\$ 215,267</b>	<b>6.4</b>	<b>7.0</b>	<b>(0.6)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$1,143,198</b>	<b>\$1,092,842</b>	<b>4.6</b>	<b>6.3</b>	<b>(1.7)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	Total				
	2012	2011	Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 518,939	\$ 504,591	2.8	3.8	(1.0)
Diabetes Care	219,245	207,759	5.5	6.5	(1.0)
Pharmaceutical Systems	283,003	268,982	5.2	7.1	(1.9)
<b>TOTAL</b>	<b>\$1,021,187</b>	<b>\$ 981,332</b>	<b>4.1</b>	<b>5.3</b>	<b>(1.2)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 323,313	\$ 306,239	5.6	6.8	(1.2)
Diagnostic Systems	306,706	299,108	2.5	3.2	(0.7)
<b>TOTAL</b>	<b>\$ 630,019</b>	<b>\$ 605,347</b>	<b>4.1</b>	<b>5.0</b>	<b>(0.9)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 261,543	\$ 255,516	2.4	2.8	(0.4)
Discovery Labware	78,069	79,828	(2.2)	(2.1)	(0.1)
<b>TOTAL</b>	<b>\$ 339,612</b>	<b>\$ 335,344</b>	<b>1.3</b>	<b>1.7</b>	<b>(0.4)</b>
<b>TOTAL REVENUES</b>	<b>\$1,990,818</b>	<b>\$1,922,023</b>	<b>3.6</b>	<b>4.6</b>	<b>(1.0)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		
	2012	2011	% Change
<b><u>BD MEDICAL</u></b>			
Medical Surgical Systems	\$ 486,015	\$ 488,825	(0.6)
Diabetes Care	211,251	195,524	8.0
Pharmaceutical Systems	135,924	119,665	13.6
<b>TOTAL</b>	<b>\$ 833,190</b>	<b>\$ 804,014</b>	<b>3.6</b>
<b><u>BD DIAGNOSTICS</u></b>			
Preanalytical Systems	\$ 325,570	\$ 319,036	2.0
Diagnostic Systems	304,650	300,431	1.4
<b>TOTAL</b>	<b>\$ 630,220</b>	<b>\$ 619,467</b>	<b>1.7</b>
<b><u>BD BIOSCIENCES</u></b>			
Cell Analysis	\$ 152,634	\$ 163,262	(6.5)
Discovery Labware	60,369	71,040	(15.0)
<b>TOTAL</b>	<b>\$ 213,003</b>	<b>\$ 234,302</b>	<b>(9.1)</b>
<b>TOTAL UNITED STATES</b>	<b>\$1,676,413</b>	<b>\$1,657,783</b>	<b>1.1</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	International				
	2012	2011	Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 555,234	\$ 528,491	5.1	6.3	(1.2)
Diabetes Care	233,913	226,118	3.4	4.2	(0.8)
Pharmaceutical Systems	349,247	349,254	—	1.1	(1.1)
<b>TOTAL</b>	<b>\$1,138,394</b>	<b>\$1,103,863</b>	<b>3.1</b>	<b>4.2</b>	<b>(1.1)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 314,365	\$ 299,832	4.8	6.5	(1.7)
Diagnostic Systems	306,177	287,771	6.4	6.8	(0.4)
<b>TOTAL</b>	<b>\$ 620,542</b>	<b>\$ 587,603</b>	<b>5.6</b>	<b>6.7</b>	<b>(1.1)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 352,510	\$ 332,997	5.9	5.9	—
Discovery Labware	90,605	81,782	10.8	9.9	0.9
<b>TOTAL</b>	<b>\$ 443,115</b>	<b>\$ 414,779</b>	<b>6.8</b>	<b>6.7</b>	<b>0.1</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$2,202,051</b>	<b>\$2,106,245</b>	<b>4.5</b>	<b>5.4</b>	<b>(0.9)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	Total				
	2012	2011	Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$1,041,249	\$1,017,316	2.4	3.0	(0.6)
Diabetes Care	445,164	421,642	5.6	6.0	(0.4)
Pharmaceutical Systems	485,171	468,919	3.5	4.3	(0.8)
<b>TOTAL</b>	<b>\$1,971,584</b>	<b>\$1,907,877</b>	<b>3.3</b>	<b>4.0</b>	<b>(0.7)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 639,935	\$ 618,868	3.4	4.2	(0.8)
Diagnostic Systems	610,827	588,202	3.8	4.1	(0.3)
<b>TOTAL</b>	<b>\$1,250,762</b>	<b>\$1,207,070</b>	<b>3.6</b>	<b>4.1</b>	<b>(0.5)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 505,144	\$ 496,259	1.8	1.8	—
Discovery Labware	150,974	152,822	(1.2)	(1.7)	0.5
<b>TOTAL</b>	<b>\$ 656,118</b>	<b>\$ 649,081</b>	<b>1.1</b>	<b>1.0</b>	<b>0.1</b>
<b>TOTAL REVENUES</b>	<b>\$3,878,464</b>	<b>\$3,764,028</b>	<b>3.0</b>	<b>3.5</b>	<b>(0.5)</b>



BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 Quarter-to-Date Fiscal 2012 Reconciliation - FX Impact  
 (Unaudited; Amounts in millions, except per share data)

	Three Months Ended March 31,					
	Reported FY2012	Reported FY2011	Reported Growth \$	Foreign Currency Translation	FXN Change	FXN Growth
REVENUES	\$ 1,991	\$ 1,922	\$ 69	\$ (19)	\$ 88	4.6%
Diluted Earnings per Share from Continuing Operations	\$ 1.38	\$ 1.38	\$ 0.00	\$ (0.04)	\$ 0.04	2.9%

*All figures rounded. Totals may not add due to rounding.*

FXN = Foreign Currency Neutral

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 Year-to-Date Fiscal 2012 Reconciliation - FX Impact  
 (Unaudited; Amounts in millions, except per share data)

	Six Months Ended March 31,					
	<u>Reported FY2012</u>	<u>Reported FY2011</u>	<u>Reported Growth \$</u>	<u>Foreign Currency Translation</u>	<u>FXN Change</u>	<u>FXN Growth</u>
REVENUES	\$ 3,878	\$ 3,764	\$ 114	\$ (18)	\$ 132	3.5%
Diluted Earnings per Share from Continuing Operations	\$ 2.59	\$ 2.72	\$ (0.13)	\$ (0.04)	\$(0.09)	-3.3%

*All figures rounded. Totals may not add due to rounding.*

FXN = Foreign Currency Neutral